Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid β production

BackgroundAlzheimer’s disease (AD)-linked protein, presenilin 1 (PS1), is present at the synapse, and the knock-out of presenilin in mice leads to synaptic dysfunction. On the other hand, synaptic activity was shown to influence PS1-dependent generation of distinct amyloid β (Aβ) species. However, the precise nature of these regulations remains unclear. The current study reveals novel role of PS1 at the synapse, and deciphers how PS1 and synaptic vesicle-associated protein, synaptotagmin 1 (Syt1) modulate each other functions in neurons via direct activity-triggered interaction. Additionally, the therapeutic potential of fostering PS1-Syt1 binding is investigated as a synapse-specific strategy for AD prevention.MethodsPS1-based cell-permeable peptide targeting PS1-Syt1 binding site was designed to inhibit PS1-Syt1 interaction in neurons. PS1 conformation, synaptic vesicle exocytosis and trafficking were assayed by fluorescence lifetime imaging microscopy (FLIM), glutamate release/synaptopHluorin assay, and fluorescence recovery after photobleaching, respectively. Syt1 level and interaction with PS1 in control and sporadic AD brains were determined by immunohistochemistry and FLIM. AAV-mediated delivery of Syt1 into mouse hippocampi was used to investigate the therapeutic potential of strengthening PS1-Syt1 binding in vivo. Statistical significance was determined using two-tailed unpaired Student’s t-test, Mann-Whitney’s U-test or two-way ANOVA followed by a Bonferroni’s post-test.ResultsWe demonstrate that targeted inhibition of the PS1-Syt1 binding in neurons, without changing the proteins’ expression level, triggers “pathogenic” conformational shift of PS1, and consequent increase in the Aβ42/40 ratio. Moreover, our data indicate that PS1, by binding directly to Syt1, regulates synaptic vesicle trafficking and facilitates exocytosis and neurotransmitter release. Analysis of human brain tissue revealed that not only Syt1 levels but also interactions between remaining Syt1 and PS1 are diminished in sporadic AD. On the other hand, overexpression of Syt1 in mouse hippocampi was found to potentiate PS1-Syt1 binding and promote “protective” PS1 conformation.ConclusionsThe study reports novel functions of PS1 and Syt1 at the synapse, and demonstrates the importance of PS1-Syt1 binding for exocytosis and safeguarding PS1 conformation. It suggests that reduction in the Syt1 level and PS1-Syt1 interactions in AD brain may present molecular underpinning of the pathogenic PS1 conformation, increased Aβ42/40 ratio, and impaired exocytosis.

[1]  C. Stevens,et al.  The Synaptotagmin C2A Domain Is Part of the Calcium Sensor Controlling Fast Synaptic Transmission , 2003, Neuron.

[2]  M. Wolfe,et al.  Alzheimer Presenilin-1 Mutations Dramatically Reduce Trimming of Long Amyloid β-Peptides (Aβ) by γ-Secretase to Increase 42-to-40-Residue Aβ* , 2014, The Journal of Biological Chemistry.

[3]  M. Arimon,et al.  Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease , 2013, Acta Neuropathologica.

[4]  H. Macarthur,et al.  Stable RNA interference of synaptotagmin I in PC12 cells results in differential regulation of transmitter release. , 2007, American journal of physiology. Cell physiology.

[5]  H. Vanderstichele,et al.  Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Xinran Liu,et al.  APP Is Cleaved by Bace1 in Pre-Synaptic Vesicles and Establishes a Pre-Synaptic Interactome, via Its Intracellular Domain, with Molecular Complexes that Regulate Pre-Synaptic Vesicles Functions , 2014, PloS one.

[7]  T. Südhof,et al.  Dynamic Binding Mode of a Synaptotagmin-1-SNARE Complex in Solution , 2015, Nature Structural &Molecular Biology.

[8]  Y. Shigeri,et al.  DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. , 1998, Molecular pharmacology.

[9]  F. Polleux,et al.  SNAREs Controlling Vesicular Release of BDNF and Development of Callosal Axons. , 2015, Cell reports.

[10]  J. Buchanan,et al.  Morphologically Docked Synaptic Vesicles Are Reduced insynaptotagmin Mutants of Drosophila , 1998, The Journal of Neuroscience.

[11]  Jie Shen,et al.  Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hippocampal neurons , 2013, Proceedings of the National Academy of Sciences.

[12]  E. Chapman,et al.  Role of synaptotagmin in Ca2+-triggered exocytosis. , 2002, The Biochemical journal.

[13]  Cong Ma,et al.  Synaptotagmin-1 C2B domain interacts simultaneously with SNAREs and membranes to promote membrane fusion , 2016, eLife.

[14]  H. Qing,et al.  Effect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD , 2016, Front. Aging Neurosci..

[15]  K. Jellinger,et al.  Synaptic pathology in alzheimer's disease: Immunological data for markers of synaptic and large dense-core vesicles , 1992, Neuroscience.

[16]  I. Ferrer,et al.  Dystrophic Neurites of Senile Plaques are Defective in Proteins Involved in Exocytosis and Neurotransmission , 1998, Journal of neuropathology and experimental neurology.

[17]  Mu-ming Poo,et al.  Neurotrophins as synaptic modulators , 2001, Nature Reviews Neuroscience.

[18]  S. Royer,et al.  Drosophila synaptotagmin I null mutants show severe alterations in vesicle populations but calcium‐binding motif mutants do not , 2006, The Journal of comparative neurology.

[19]  B. Hyman,et al.  Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation , 2004, Nature Medicine.

[20]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[21]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[22]  David M Holtzman,et al.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. , 2005, Neuron.

[23]  B. Hyman,et al.  Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein , 2005, The Journal of Neuroscience.

[24]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[25]  G. Jicha,et al.  Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  T. Sudhof,et al.  The synaptic vesicle cycle. , 2004, Annual review of neuroscience.

[27]  K. P. Kepp,et al.  The dynamic mechanism of presenilin-1 function: Sensitive gate dynamics and loop unplugging control protein access , 2016, Neurobiology of Disease.

[28]  K. Mirnics,et al.  Presenilin-1-Dependent Transcriptome Changes , 2005, The Journal of Neuroscience.

[29]  Rudolph E. Tanzi,et al.  Synaptotagmins interact with APP and promote Aβ generation , 2015, Molecular Neurodegeneration.

[30]  Phillip B. Jones,et al.  Reciprocal relationship between APP positioning relative to the membrane and PS1 conformation , 2011, Molecular Neurodegeneration.

[31]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[32]  Brian J Bacskai,et al.  Fluorescence resonance energy transfer determinations using multiphoton fluorescence lifetime imaging microscopy to characterize amyloid-beta plaques. , 2003, Journal of biomedical optics.

[33]  Edwin R Chapman,et al.  How does synaptotagmin trigger neurotransmitter release? , 2008, Annual review of biochemistry.

[34]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[35]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[36]  Ryohei Yasuda,et al.  Imaging spatiotemporal dynamics of neuronal signaling using fluorescence resonance energy transfer and fluorescence lifetime imaging microscopy , 2007, Current Opinion in Neurobiology.

[37]  M. Bursavich,et al.  Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon? , 2016, Journal of medicinal chemistry.

[38]  Leon Lagnado,et al.  Imaging phluorin-based probes at hippocampal synapses. , 2008, Methods in molecular biology.

[39]  T. Morgan,et al.  Chronic Overexpression of the Calcineurin Inhibitory Gene DSCR1 (Adapt78) Is Associated with Alzheimer's Disease* , 2001, The Journal of Biological Chemistry.

[40]  T. Südhof,et al.  Presenilins are Essential for Regulating Neurotransmitter Release , 2009, Nature.

[41]  J. Herms,et al.  Analyzing dendritic spine pathology in Alzheimer’s disease: problems and opportunities , 2015, Acta Neuropathologica.

[42]  Hans Blom,et al.  Super-resolution microscopy reveals γ-secretase at both sides of the neuronal synapse , 2016, Acta Neuropathologica Communications.

[43]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[44]  Yong Yu,et al.  DSCR1/RCAN1 regulates vesicle exocytosis and fusion pore kinetics: implications for Down syndrome and Alzheimer's disease. , 2008, Human molecular genetics.

[45]  María J. Ramírez,et al.  Decreased rabphilin 3A immunoreactivity in Alzheimer’s disease is associated with Aβ burden , 2014, Neurochemistry International.

[46]  M. Takeda,et al.  γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. , 2013, Cell reports.

[47]  S. Achilefu,et al.  Fluorescence lifetime measurements and biological imaging. , 2010, Chemical reviews.

[48]  Dietmar Riedel,et al.  Synaptotagmin-1 Docks Secretory Vesicles to Syntaxin-1/SNAP-25 Acceptor Complexes , 2009, Cell.

[49]  E. Masliah,et al.  Synaptic and neuritic alterations during the progression of Alzheimer's disease , 1994, Neuroscience Letters.

[50]  Thin, stubby or mushroom: spine pathology in Alzheimer's disease. , 2009, Current Alzheimer research.

[51]  L. Martin,et al.  Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer’s disease brains , 2000, Journal of the Neurological Sciences.

[52]  Leon Lagnado,et al.  Optical reporters of synaptic activity in neural circuits , 2011, Experimental physiology.

[53]  N. Hirokawa,et al.  Visualization of the Dynamics of Synaptic Vesicle and Plasma Membrane Proteins in Living Axons , 1998, The Journal of cell biology.

[54]  H. Steiner,et al.  Substrate recruitment of γ‐secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping , 2016, The EMBO journal.

[55]  Antonio G. García,et al.  Smaller quantal size and faster kinetics of single exocytotic events in chromaffin cells from the APP/PS1 mouse model of Alzheimer's disease. , 2012, Biochemical and biophysical research communications.

[56]  B. Hyman,et al.  Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta , 2016, BMC Biology.

[57]  S. DeKosky,et al.  Structural correlates of cognition in dementia: quantification and assessment of synapse change. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[58]  H. Neumann,et al.  Breakdown of Axonal Synaptic Vesicle Precursor Transport by Microglial Nitric Oxide , 2005, The Journal of Neuroscience.

[59]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[60]  Douglas B. Ehlenberger,et al.  Automated Three-Dimensional Detection and Shape Classification of Dendritic Spines from Fluorescence Microscopy Images , 2008, PloS one.

[61]  A. Iwai [Gamma-secretase inhibitors and modulators]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[62]  J. Bockaert,et al.  Endogenous Amino Acid Release from Cultured Cerebellar Neuronal Cells: Effect of Tetanus Toxin on Glutamate Release , 1989, Journal of neurochemistry.

[63]  T. Südhof,et al.  Complexin Controls the Force Transfer from SNARE Complexes to Membranes in Fusion , 2009, Science.

[64]  B. Hyman,et al.  Allosteric Modulation of PS1/γ-Secretase Conformation Correlates with Amyloid β42/40 Ratio , 2009, PloS one.

[65]  R B Sutton,et al.  Functional analysis of the interface between the tandem C2 domains of synaptotagmin-1 , 2016, Molecular biology of the cell.

[66]  J. C. Kim,et al.  Decreased dendritic spine density as a consequence of tetanus toxin light chain expression in single neurons in vivo , 2013, Neuroscience Letters.

[67]  B. Hyman,et al.  Monitoring proteins in intact cells. , 2003, Science of aging knowledge environment : SAGE KE.

[68]  Xulun Zhang,et al.  Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2010, Neuron.

[69]  Nick C Fox,et al.  Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease , 2015, The Journal of experimental medicine.

[70]  O. Berezovska,et al.  Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation , 2016, Molecular medicine.

[71]  T. Iwatsubo,et al.  Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1 , 2011, The EMBO journal.

[72]  Kira E. Poskanzer,et al.  Discrete Residues in the C2B Domain of Synaptotagmin I Independently Specify Endocytic Rate and Synaptic Vesicle Size , 2006, Neuron.

[73]  Alex J Walsh,et al.  Temporal binning of time-correlated single photon counting data improves exponential decay fits and imaging speed. , 2016, Biomedical optics express.

[74]  Fergil Mills,et al.  Activity-dependent secretion of progranulin from synapses , 2013, Journal of Cell Science.

[75]  R. Terry Cell death or synaptic loss in Alzheimer disease. , 2000, Journal of neuropathology and experimental neurology.

[76]  K. Blennow,et al.  Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? , 1996, Molecular and chemical neuropathology.

[77]  Elisha Moses,et al.  Network synchronization in hippocampal neurons , 2016, Proceedings of the National Academy of Sciences.

[78]  P. Castillo,et al.  APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses , 2015, eLife.

[79]  K. Pratt,et al.  A Novel Role for γ-Secretase: Selective Regulation of Spontaneous Neurotransmitter Release from Hippocampal Neurons , 2011, The Journal of Neuroscience.

[80]  B. Hyman,et al.  Neuronal activity and secreted amyloid β lead to altered amyloid β precursor protein and presenilin 1 interactions , 2013, Neurobiology of Disease.

[81]  P. Koulen,et al.  The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. , 2008, The international journal of biochemistry & cell biology.